Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRE: Concurrent Radiotherapy and Palbociclib in Breast Cancer
NCT03691493Phase 2Completed
- Sponsor
- Emory University
- Start
- Feb 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib in breast cancer, sponsored by Emory University. Primary endpoint: Response Rate at 3 months. Started Feb 2019; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03691493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03691493.